Trevi Therapeutics reports positive results from Phase 2 trial for treatment of prurigo nodularis

Trevi Therapeutics, a late-stage clinical development company developing oral Nalbuphine ER for chronic pruritus conditions, has reported positive results from its Phase 2 trial for the treatment of moderate-to-severe prurigo nodularis (PN).

Source: Drug Development Technology - October 13, 2016 Category: Pharmaceuticals Source Type: news